TaiMed Biologics (TPEX: 4147) today (May 25) held its 2026 Annual Shareholders’ Meeting, during which shareholders approved the Company’s 2025 Business Report and Financial Statements, as well as the approved the proposal for offsetting losses for fiscal year 2025. In addition, several important resolutions were approved, including the proposal to lift the non-compete restrictions for directors and the proposal for the private placement of common shares, demonstrating the Company’s commitment to strengthening its capital structure, accelerating global market expansion, and advancing its long-term growth strategy.

TaiMed stated that the Company is actively advancing the global clinical development and licensing partnerships for its core long-acting HIV dual-antibody therapy, TMB-365/380. Enrollment in the Phase 2b clinical trial has progressed smoothly, and the Company has officially completed Last Patient In (LPI). The study will now move into continual dosing and the critical data analysis stage, with interim data readout expected by the end of 2026. The Company also plans to present the results at the internationally renowned HIV scientific conference, the Conference on Retroviruses and Opportunistic Infections (CROI).

Regarding the approved private placement of common shares, TaiMed noted that the fundraising initiative is intended to support future operational and strategic development needs, including international licensing collaborations, strategic alliances, advancement of its long-acting antibody platform, and related new drug development programs. The Company will prudently evaluate market conditions and the qualifications of strategic investors, with the goal of introducing partners that possess industry resources and international market advantages to further enhance TaiMed’s competitiveness and global growth momentum.

Dr. Jimmy Chang, CEO of TaiMed Biologics, stated:
“2026 will represent an important value-inflection year for TaiMed. In addition to continuing to advance the clinical development and licensing progress of TMB-365/380, we are also expanding our TMB-365-ADC platform into HIV cure and autoimmune diseases, CDMO business, international collaborations, and capital market initiatives. With our long-acting antibody platform at the core, we will continue progressing toward our goal of becoming a globally innovative biotechnology company.”

TaiMed emphasized its gratitude for the long-term support of shareholders. The management team will continue to focus on advancing its core HIV therapeutics and development pipeline, as well as progressing clinical programs and commercial licensing negotiations, with the goal of creating long-term maximum value for shareholders.